# A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age

> **NCT02719743** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 185 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).

## Key facts

- **NCT ID:** NCT02719743
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-07
- **Primary completion:** 2018-02-13
- **Final completion:** 2018-02-13
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719743, "A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02719743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*